← Back to Search

Small Molecule

Deucrictibant for Angioedema(RAPIDe-2 Trial)

Study site, Ashkelon, Israel
Targeting 12 different conditionsdeucrictibant medium dose +3 morePhase 2 & 3RecruitingLed by Marcus Maurer, Prof MDResearch Sponsored by Pharvaris Netherlands B.V.

RAPIDe-2 Trial Summary

This trial will study the long-term effects of a drug for hereditary angioedema, a condition where people have swellings in different parts of the body.

Eligible Conditions
  • Hereditary Angioedema
  • C1 Esterase Inhibitor Deficiency

RAPIDe-2 Trial Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below
You have been diagnosed with hereditary angioedema (HAE) type I or II.

RAPIDe-2 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from enrollment through study completion, up to 40 months (dependent on time of enrollment).
This trial's timeline: 3 weeks for screening, Varies for treatment, and from enrollment through study completion, up to 40 months (dependent on time of enrollment). for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Blood pressure
Body temperature
Heart Rate
+1 more
Secondary outcome measures
Change in Mean symptom complex severity (MSCS) score
Change of VAS-3 score and individual VAS score from pre-treatment to 4 h post-treatment for non-laryngeal attacks
Proportion of PHA-022121-treated attacks requiring a second dose of PHA-022121
+6 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

RAPIDe-2 Trial Design

4Treatment groups
Experimental Treatment
Group I: Part B: Selected doseExperimental Treatment1 Intervention
Single dose of deucrictibant
Group II: Part A: Medium doseExperimental Treatment1 Intervention
Single medium dose of deucrictibant
Group III: Part A: Low doseExperimental Treatment1 Intervention
Single low dose of deucrictibant
Group IV: Part A: High doseExperimental Treatment1 Intervention
Single high dose of deucrictibant

Find a Location

Who is running the clinical trial?

Pharvaris Netherlands B.V.Lead Sponsor
3 Previous Clinical Trials
134 Total Patients Enrolled
Marcus Maurer, Prof MDPrincipal InvestigatorCharite University, Berlin, Germany
1 Previous Clinical Trials
74 Total Patients Enrolled

Media Library

PHA-022121 (Small Molecule) Clinical Trial Eligibility Overview. Trial Name: NCT05396105 — Phase 2 & 3
Hereditary Angioedema Research Study Groups: Part A: Medium dose, Part A: High dose, Part A: Low dose, Part B: Selected dose
Hereditary Angioedema Clinical Trial 2023: PHA-022121 Highlights & Side Effects. Trial Name: NCT05396105 — Phase 2 & 3
PHA-022121 (Small Molecule) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05396105 — Phase 2 & 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are new test subjects needed for this experiment?

"This clinical trial is actively looking for patients, with the original posting on July 19th, 2022 and the most recent update on October 25th, 2022."

Answered by AI

Who else is applying?

What site did they apply to?
Study site
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?

What questions have other patients asked about this trial?

Why did patients apply to this trial?

Medical personnel lacking informstion on this particular occurance. Need help now.
PatientReceived 2+ prior treatments
~38 spots leftby Dec 2024